Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2022
ABL Bio and Sanofi announce Parkinson’s treatment collaboration
ABL Bio announced a collaboration and worldwide license agreement with Sanofi to develop and commercialize ABL301, a preclinical-stage treatment candidate for Parkinson’s disease and other potential indications. Sanofi is to receive worldwide exclusive development and commercialization rights once the transaction becomes effective.
2019
GenScript and ABL Bio sign antibody-development partnership
GenScript and South Korean biotechnology company ABL Bio signed an agreement to collaborate on the development of two bispecific-antibody projects. GenScript will license antibody assets and its platform to ABL Bio and provide preclinical pharmaceutical research and clinical-sample manufacturing services as the exclusive CDMO supplier for the projects.
2019
GenScript and ABL Bio agree to develop bispecific antibodies
GenScript and South Korean biotechnology company ABL Bio signed an agreement for strategic collaboration on the development of two bispecific antibody programs. GenScript will license antibody and platform technologies to ABL Bio and provide exclusive preclinical pharmaceutical research and clinical-sample production services for the molecules.